香港交易及結算所有限公司和香港聯合交易所有限公司對本公告的內容概不負責，對其準確性 或完整性亦不發表任何聲明，並明確表示，概不對因本公告全部或任何部分內容而產生或因依賴 該等內容而引致的任何損失承擔任何責任。 * 僅供識別 上 海 醫 藥 集 團 股 份 有 限 公 司 Shanghai Pharmaceuticals Holding Co., Ltd. * （於中華人民共和國註冊成立的股份有限公司） （股份代碼：02607） 海外監管公告 本公告乃根據香港聯合交易所有限公司證券上市規則第 13.10B 條而作出。 茲載列上海醫藥集團股份有限公司（「本公司」）在上海證券交易所網站(http://www.sse.com.cn) 刊登的《上海醫藥集團股份有限公司關於 2019 年 A 股股票期權激勵計畫預留股票期權第三 個行權期 2025 年第一季度自主行權結果公告》、《上海醫藥集團股份有限公司關於向特定對 象發行限售股上市流通的公告》、《國投證券股份有限公司關於上海醫藥集團股份有限公司向 特定對象發行限售股上市流通的核查意見》僅供參閱。 承董事會命 上海醫藥集團股份有限公司 楊秋華 董事長 中國上海，2025 ...

香港交易及結算所有限公司和香港聯合交易所有限公司對本公告的內容概不負責，對其準確性 或完整性亦不發表任何聲明，並明確表示，概不對因本公告全部或任何部分內容而產生或因依賴 該等內容而引致的任何損失承擔任何責任。 上 海 醫 藥 集 團 股 份 有 限 公 司 Shanghai Pharmaceuticals Holding Co., Ltd. * （於中華人民共和國註冊成立的股份有限公司） （股份代碼：02607） 海外監管公告 本公告乃根據香港聯合交易所有限公司證券上市規則第 13.10B 條而作出。 茲載列上海醫藥集團股份有限公司（「本公司」）在上海證券交易所網站 (http://www.sse.com.cn)刊登的《上海醫藥集團股份有限公司關於高級管理人員離 任的公告》僅供參閱。 承董事會命 上海醫藥集團股份有限公司 楊秋華 董事長 中國上海，2025 年 4 月 1 日 於本公告日期，本公司的執行董事為楊秋華先生、沈波先生、李永忠先生及董明 先生；非執行董事為張文學先生；以及獨立非執行董事為顧朝陽先生、霍文遜先 生、王忠先生及萬鈞女士。 * 僅供識別 证券代码：601607 证券简称：上海医药 公告编号 ...

EF001 EF001 免責聲明 | 香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確性或完整性亦不發表任何聲明，並明確表示，概不對因 | | | --- | --- | | 公告全部或任何部份內容而產生或因倚賴該等內容而引致的任何損失承擔任何責任。 | | | 股票發行人現金股息公告 | | | 發行人名稱 | 上海醫藥集團股份有限公司 | | 股份代號 | 02607 | | 多櫃檯股份代號及貨幣 | 不適用 | | 相關股份代號及名稱 | 不適用 | | 公告標題 | 截至2024年12月31日止年度之末期股息 | | 公告日期 | 2025年3月28日 | | 公告狀態 | 新公告 | | 股息信息 | | | 股息類型 | 末期 | | 股息性質 | 普通股息 | | 財政年末 | 2024年12月31日 | | 宣派股息的報告期末 | 2024年12月31日 | | 宣派股息 | 每 10 股 2.9 RMB | | 股東批准日期 | 有待公佈 | | 香港過戶登記處相關信息 | | | 派息金額及公司預設派發貨幣 | 有待公佈 | | 匯率 | 有待公佈 | | ...

香港交易及結算所有限公司和香港聯合交易所有限公司對本公告的內容概不負責，對其準確性 或完整性亦不發表任何聲明，並明確表示，概不對因本公告全部或任何部分內容而產生或因依賴 該等內容而引致的任何損失承擔任何責任。 上 海 醫 藥 集 團 股 份 有 限 公 司 Shanghai Pharmaceuticals Holding Co., Ltd. * （於中華人民共和國註冊成立的股份有限公司） （股份代碼：02607） 海外監管公告 本公告乃根據香港聯合交易所有限公司證券上市規則第 13.10B 條而作出。 茲載列上海醫藥集團股份有限公司（「本公司」）在上海證券交易所網站 (http://www.sse.com.cn)刊登的《上海醫藥集團股份有限公司第八屆董事會第二十 次會議決議公告》、《上海醫藥集團股份有限公司第八屆監事會第十一次會議決議 公告》、《上海醫藥集團股份有限公司 2025 年度日常關聯交易公告》、《上海醫藥 集團股份有限公司關於註銷公司 2019 年 A 股股票期權激勵計畫首次授予股票期 權第三個行權期及預留股票期權第二個行權期已到期未行權的股票期權的公告》、 《國浩律師（上海）事務所關於上海醫藥登出 ...

Financial Performance - Shanghai Pharmaceuticals reported its annual performance for the year ending December 31, 2024, in accordance with Chinese accounting standards[3]. - Revenue for 2023 reached RMB 260.30 billion, a 12.2% increase from RMB 231.98 billion in 2022[20]. - Pre-tax profit for 2023 was RMB 7.05 billion, a decrease of 20% compared to RMB 8.81 billion in 2022[20]. - The company achieved a net profit of RMB 5.17 billion in 2023, down from RMB 6.99 billion in 2022, reflecting a decline of 26.2%[20]. - In 2024, the company achieved a total revenue of RMB 275.251 billion, representing a year-on-year growth of 5.75%[28]. - The net profit attributable to shareholders reached RMB 4.553 billion, an increase of 20.82% year-on-year[29]. - The pharmaceutical industrial segment reported a sales revenue of RMB 23.731 billion, a decline of 9.62% year-on-year, while the pharmaceutical commercial segment achieved RMB 251.520 billion, a growth of 7.47%[28]. - The company reported a net operating cash flow of RMB 5.827 billion, up 11.39% year-on-year, indicating sustained high-quality development[31]. - The company's operating revenue for the current period reached ¥275.25 billion, an increase of 5.75% compared to ¥260.30 billion in the same period last year[58]. - Operating costs increased by 6.84% to ¥244.62 billion from ¥228.97 billion, driven by the rise in sales revenue[58]. Research and Development - Research and development investment totaled RMB 2.818 billion, with R&D expenses of RMB 2.394 billion, reflecting an 8.64% increase year-on-year[30]. - The company has established a new product planning department to optimize its product pipeline, focusing on areas such as immunology, oncology, cardiovascular, digestive metabolism, and anti-infection diseases[36]. - The company is focusing on optimizing its product pipeline in biopharmaceuticals, chemical drugs, traditional Chinese medicine, and rare diseases[24]. - The company has 5 innovative drugs in clinical phase III and 32 projects in various clinical stages[37]. - The company is actively exploring multiple rare disease areas with its innovative antibody drugs, aiming to provide effective treatments for patients[40]. - The company is committed to continuous innovation and market expansion through strategic R&D efforts[74]. - The company has a diverse pipeline with drugs targeting various therapeutic areas, including cardiovascular, diabetes, and infectious diseases[76]. Strategic Initiatives - The company aims to become a respected leading brand in pharmaceutical manufacturing and health services[5]. - The company is advancing its digital transformation with the establishment of smart factories, including the first "Future Factory" in the Zhejiang pharmaceutical industry[24]. - The company is committed to building an innovative ecosystem through collaborations with top universities and research institutions[23]. - The establishment of the Shanghai Frontier innovation ecosystem has successfully attracted 15 partner organizations and innovation enterprises[34]. - Strategic collaborations in cell and gene therapy are progressing, with partnerships signed with several medical institutions to advance product innovation and industrialization[35]. - The company is actively expanding into international markets and adjusting its strategies in response to healthcare cost control and payment reforms[90]. Corporate Governance - The board of directors has reviewed the annual performance report, ensuring its accuracy and completeness[3]. - The board of directors includes both executive and independent non-executive members, ensuring diverse governance[4]. - The company has confirmed the independence of its independent non-executive directors as per Hong Kong listing rules[103]. - The company has no significant contracts with controlling shareholders during the reporting period[107]. Market Position and Recognition - The company was ranked 411th in the Fortune Global 500 and recognized in multiple industry rankings, including the top 50 global pharmaceutical companies[28]. - The company is positioned as one of the top 50 global pharmaceutical enterprises, transitioning from a generic drug company to a research-driven pharmaceutical enterprise[51]. Employee and Management - The company employed a total of 49,402 staff, with 19,370 in sales and 15,152 in production roles[173]. - The company has established a differentiated compensation system for various employee categories, effectively motivating all employees to enhance company performance[174]. - The total pre-tax compensation for executives during the reporting period amounted to CNY 1,796.17 million[185]. - The company has conducted 25 types of training projects with 141 sessions, completing over 100,000 training instances, and launched a digital learning platform with over 10,000 projects and 5,000 courses[178]. Financial Management - The company has increased investment in mergers and acquisitions, actively expanding international business, with a signed agreement to acquire 10% of the shares of Huanlong Pharmaceutical by December 2024[46]. - The company has registered 18 new overseas products this year, bringing the total to 25, with one product approved[46]. - The company has established internal compliance and risk management policies to ensure adherence to legal requirements[162]. - The company maintains strong relationships with stakeholders, including employees, customers, and suppliers, to achieve sustainable development[163]. Future Outlook - The company provided an optimistic outlook, projecting a revenue growth of 20% for the next quarter, targeting $1.44 billion[3]. - The company aims to enhance its core competitiveness and contribute to the "Healthy China 2030" initiative by improving its multi-level pharmaceutical distribution network and digital supply chain capabilities[87]. - By 2025, the company plans to strengthen its industrial foundation and enhance the value contribution of its traditional Chinese medicine, micro-ecology, and health businesses, while focusing on the integration of research and development[89].

上海醫藥集團股份有限公司 Shanghai Pharmaceuticals Holding Co., Ltd. * （於中華人民共和國註冊成立的股份有限公司） (股份代碼: 02607) 董事名單及其角色和職能 於 2025 年 3 月 27 日，上海醫藥集團股份有限公司董事會(「董事會」)成員列示如下： 執行董事: 楊秋華先生（董事長） 沈波先生 李永忠先生 董明先生 非執行董事: 張文學先生 獨立非執行董事: 顧朝陽先生 霍文遜先生 王忠先生 萬鈞女士 戰略委員會: 楊秋華先生（召集人） 張文學先生 王忠先生 提名委員會: 霍文遜先生（召集人） 沈波先生 顧朝陽先生 萬鈞女士 審計委員會: 顧朝陽先生（召集人） 霍文遜先生 王忠先生 薪酬與考核委員會: 王忠先生（召集人） 楊秋華先生 顧朝陽先生 中國上海，2025 年 3 月 27 日 * 僅供識別 ...

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告之內容概不負責，對其 準確性或完整性亦不發表任何聲明，並明確表示，概不對因本公告全部或任何部分內容 而產生或因依賴該等內容而引致之任何損失承擔任何責任。 上海醫藥集團股份有限公司 Shanghai Pharmaceuticals Holding Co., Ltd.* ( 於中華人民共和國註冊成立的股份有限公司 ) 承董事會命 上海醫藥集團股份有限公司 楊秋華 董事長 中國上海，2025年3月27日 1 於本公告日期，本公司的執行董事為楊秋華先生、沈波先生、李永忠先生及董明先生；非 執行董事為張文學先生；以及獨立非執行董事為顧朝陽先生、霍文遜先生、王忠先生及萬 鈞女士。 * 僅供識別 (股份代碼: 02607) 董事會委員會組成變動 茲提述上海醫藥集團股份有限公司（「本公司」）日期為二零二五年三月十三日的公告，內 容有關（其中包括）委任萬鈞女士為本公司第八屆董事會（「董事會」）獨立非執行董事。 董事會欣然宣佈，萬鈞女士已獲委任為董事會提名委員會委员，該等委任自2025年3月27日起 生效。 ...

編號：公司-董-016-2025-V3 上海醫藥集團股份有限公司 董事會提名委員會實施細則 第三條 本細則所稱"董事"是指本公司的董事會全體董事，包括外部董 事和獨立董事。 -/0 1 第二章 人員組成 第四條 提名委員會成員由不少於三（3）名董事組成，其中獨立董事應 占半數以上。提名委員會應委任至少一名不同性別的董事。 第五條 提名委員會委員由董事長、二分之一（1/2）以上獨立董事或者 全體董事的三分之一（1/3）以上提名，並由董事會選舉產生。 第一章 總則 第一條 為規範上海醫藥集團股份有限公司（以下簡稱"公司"或"本公 司"）董事的產生，優化董事會組成，完善公司治理結構，根據《中華人民共和 國公司法》、《上市公司獨立董事管理辦法》、《上市公司治理準則》、《香港聯合交 易所有限公司證券上市規則》（"《聯交所上市規則》"）、《上海證券交易所股 票上市規則》、《上海證券交易所上市公司自律監管指引第 1 號——規範運作》、 《公司章程》、《董事會議事規則》及其他有關規定，公司特設立董事會提名委員 會（"提名委員會"），並制定本細則。 第二條 提名委員會是董事會下設的專門工作機構，主要負責對公司董事 的人選、選擇 ...

Financial Performance - Shanghai Pharmaceuticals achieved a total cash dividend distribution of CNY 1,371,646,936.91, accounting for 30.13% of the net profit attributable to shareholders for the year[12]. - The company reported a revenue of RMB 100 billion for the fiscal year 2024, representing a year-on-year growth of 15%[29]. - The company achieved a net profit of RMB 10 billion, an increase of 20% compared to the previous year[29]. - The company reported a gross margin of 40%, maintaining stability compared to the previous year[29]. - The company achieved operating revenue of CNY 275.25 billion in 2024, representing a year-on-year growth of 5.75%[30]. - Net profit attributable to shareholders reached CNY 4.55 billion, an increase of 20.82% compared to the previous year[30]. - The basic earnings per share (EPS) for 2024 was CNY 1.23, reflecting a growth of 20.59% year-on-year[31]. - The weighted average return on equity (ROE) improved to 6.50%, up by 0.94 percentage points from the previous year[31]. - The company reported a net cash flow from operating activities of CNY 5.83 billion, an increase of 11.39% compared to 2023[30]. - The company reported a significant increase in investment income, which rose by 658.44% to approximately ¥380.43 million from a loss of ¥68.12 million in the previous year[75]. Research and Development - The company is investing RMB 1 billion in R&D for new technologies, focusing on biopharmaceuticals and personalized medicine[29]. - Research and development investment totaled 2.818 billion yuan, with R&D expenses at 2.394 billion yuan, reflecting an 8.64% year-on-year increase[41]. - The company has established a new product planning department to optimize its product pipeline, focusing on areas such as immunology, oncology, and cardiovascular diseases[44]. - As of the end of the reporting period, there were 54 new drug pipelines under clinical application, including 40 innovative drugs and 14 improved new drugs[45]. - The company has made significant progress in its innovative drug pipeline, with 1 project submitted for market approval and 5 projects in Phase III clinical trials[44]. - The company is focusing on expanding its product pipeline with new drugs targeting various diseases, including cancer and autoimmune disorders[107]. - The company received orphan drug designation from the FDA for SRD4610, indicated for amyotrophic lateral sclerosis (ALS)[110]. - The company has ongoing clinical trials for several new drugs, including I001-A for diabetic nephropathy in Phase II[102]. Market Expansion and Strategy - The company expanded its international business, completing multiple product registrations and sales in Southeast Asia and the Middle East, with its Thailand subsidiary achieving its first-year sales target[6]. - Market expansion efforts include entering two new provinces in China, projected to contribute an additional RMB 2 billion in revenue[29]. - The company is actively pursuing mergers and acquisitions, including a signed agreement to acquire a 10% stake in Hehuang Pharmaceutical[6]. - The company is considering strategic acquisitions to enhance its product portfolio, with a budget of RMB 3 billion allocated for potential deals[29]. - The company aims for a revenue growth guidance of 12-15% for the fiscal year 2025[29]. - The company plans to launch three new products in the next quarter, targeting a market share increase of 10% in the respective segments[29]. Innovation and Quality Management - The company launched 1 innovative drug approved for market and made significant clinical breakthroughs in multiple projects within the biopharmaceutical sector[4]. - The company received 167 quality awards at national and provincial levels, reflecting its commitment to quality management in production[5]. - Shanghai Pharmaceuticals' digital transformation efforts led to the recognition of its "smart factory" as a national excellence-level facility[5]. - The Shanghai Frontier innovation ecosystem has successfully integrated 15 partner organizations, enhancing the company's innovation capabilities[41]. - The company has signed strategic cooperation agreements with several institutions to advance the industrialization of cell therapy products[43]. Corporate Governance and Shareholder Relations - The company adheres to the requirements of the Company Law and relevant regulations, ensuring equal treatment of all shareholders and independent operation of the board and supervisory committee[143]. - The board consists of 9 members, including 4 independent directors with expertise in accounting, pharmaceuticals, and management, meeting governance standards[143]. - The company emphasizes transparency and timely information disclosure, implementing management systems for investor relations and information disclosure[143]. - The company has not reported any conflicts of interest or competition issues with its controlling shareholders[144]. - The company held its first extraordinary shareholders' meeting in March 2024, with all proposals approved[145]. Environmental Sustainability - The company invested ¥11,805.12 million in environmental protection during the reporting period[192]. - The company has established environmental protection mechanisms and is classified as a key pollutant discharge unit[192]. - The company is actively monitoring and reporting its emissions to ensure compliance with environmental regulations[194]. - The company aims to enhance its environmental sustainability practices in future operations[192]. - The company has implemented a comprehensive wastewater treatment system that processes wastewater through aerobic biological treatment before discharging into municipal networks[199]. Employee Development and Training - The company has completed over 100,000 training sessions in 2024, with 25 project types and 141 classes, enhancing employee skills and compliance training[173]. - The digital learning platform "Shangyao e School" has launched over 10,000 projects and 5,000 courses, supporting offline learning initiatives[173]. - In 2024, the company conducted comprehensive training for over 2,700 new employees through a main/sub-venue format, ensuring full coverage[173]. - The company has established a differentiated compensation system for various roles, including management, marketing, R&D, quality management, and production personnel[170].

香港交易及結算所有限公司和香港聯合交易所有限公司對本公告的內容概不負責，對其準確性 或完整性亦不發表任何聲明，並明確表示，概不對因本公告全部或任何部分內容而產生或因依賴 該等內容而引致的任何損失承擔任何責任。 上 海 醫 藥 集 團 股 份 有 限 公 司 Shanghai Pharmaceuticals Holding Co., Ltd. * （於中華人民共和國註冊成立的股份有限公司） （股份代碼：02607） 海外監管公告 本公告乃根據香港聯合交易所有限公司證券上市規則第 13.10B 條而作出。 茲載列上海醫藥集團股份有限公司（「本公司」）在上海證券交易所網站(http://www.sse.com.cn) 刊登的《上海醫藥集團股份有限公司關於召開 2024 年度業績說明會的公告》、《上海醫藥集 團股份有限公司關於 2019 年 A 股股票期權激勵計畫預留股票期權第三個行權期限制行權期 間的提示性公告》僅供參閱。 承董事會命 上海醫藥集團股份有限公司 楊秋華 董事長 中國上海，2025 年 3 月 27 日 於本公告日期，本公司的執行董事為楊秋華先生、沈波先生、李永忠先生及董明 先生；非執行董事為張文學先 ...